| Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities T Grosser, S Fries, GA FitzGerald The Journal of clinical investigation 116 (1), 4-15, 2006 | 1350 | 2006 |
| COX-2-derived prostacyclin confers atheroprotection on female mice KM Egan, JA Lawson, S Fries, B Koller, DJ Rader, EM Smyth, ... Science 306 (5703), 1954-1957, 2004 | 530 | 2004 |
| Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin T Grosser, S Fries, JA Lawson, SC Kapoor, GR Grant, GA FitzGerald Circulation 127 (3), 377-385, 2013 | 308 | 2013 |
| Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism KM Egan, M Wang, MB Lucitt, AM Zukas, E Puré, JA Lawson, ... Circulation 111 (3), 334-342, 2005 | 244 | 2005 |
| Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 S Fries, T Grosser, TS Price, JA Lawson, S Kapoor, S DeMarco, ... Gastroenterology 130 (1), 55-64, 2006 | 168 | 2006 |
| COX-2–derived prostacyclin modulates vascular remodeling RD Rudic, D Brinster, Y Cheng, S Fries, WL Song, S Austin, TM Coffman, ... Circulation research 96 (12), 1240-1247, 2005 | 140 | 2005 |
| Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans WL Song, M Wang, E Ricciotti, S Fries, Y Yu, T Grosser, M Reilly, ... Journal of Biological Chemistry 283 (2), 1179-1188, 2008 | 102 | 2008 |
| Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs X Li, S Fries, R Li, JA Lawson, KJ Propert, SL Diamond, IA Blair, ... Proceedings of the National Academy of Sciences 111 (47), 16830-16835, 2014 | 87 | 2014 |
| Novel eicosapentaenoic acid-derived F3-isoprostanes as biomarkers of lipid peroxidation WL Song, G Paschos, S Fries, MP Reilly, Y Yu, J Rokach, CT Chang, ... Journal of Biological Chemistry 284 (35), 23636-23643, 2009 | 68 | 2009 |
| The cardiovascular pharmacology of COX-2 inhibition S Fries, T Grosser ASH Education Program Book 2005 (1), 445-451, 2005 | 67 | 2005 |
| Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin R Li, S Fries, X Li, T Grosser, SL Diamond Clinical chemistry 59 (8), 1195-1204, 2013 | 46 | 2013 |
| Cyclooxygenase inhibitors repress vascular hyaluronan‐synthesis in murine atherosclerosis and neointimal thickening A Marzoll, N Nagy, L Wördehoff, G Dai, S Fries, V Lindner, T Grosser, ... Journal of Cellular and Molecular Medicine 13 (9b), 3713-3719, 2009 | 18 | 2009 |
| Thromboxane generation T Grosser, S Fries, GA FitzGerald Platelets, 565-574, 2007 | 15 | 2007 |
| Considerations for the safe operation of schools during the coronavirus pandemic R Lordan, S Prior, E Hennessy, A Naik, S Ghosh, GK Paschos, C Skarke, ... Frontiers in public health 9, 751451, 2021 | 14 | 2021 |
| Cyclooxygenase-2-derived prostacyclin confers atheroprotection on female mice KM Egan, JA Lawson, S Fries, B Koller, DJ Rader, EM Smyth, ... Obstetrical & gynecological survey 60 (5), 309-310, 2005 | 11 | 2005 |
| Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease L Zhao, T Grosser, S Fries, L Kadakia, H Wang, J Zhao, R Falotico Expert Review of Clinical Immunology 2 (4), 649-658, 2006 | 9 | 2006 |
| Platelet Prostanoids and their receptors S Fries, T Grosser Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology …, 2017 | 3 | 2017 |
| Response to Letters Regarding Article,“Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin” T Grosser, S Fries, JA Lawson, SC Kapoor, GR Grant, GA FitzGerald Circulation 128 (12), e191-e191, 2013 | 3 | 2013 |
| consumption of aspirin and naproxen by platelet donors and the quality of platelet transfusion X Li, S Fries, BS Sachais, A Cuker, IA Blair, T Grosser Circulation 132 (suppl_3), A15635-A15635, 2015 | 2 | 2015 |
| Inter-and intraindividual variability in the pharmacological response to inhibitors of cyclooxygenase-2 S Fries, T Grosser, JA Lawson, S DeMarco, SC Kapoor, GA FitzGerald ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24 (5), E3-E3, 2004 | 2 | 2004 |
